CLAIMS

What is claimed is:

1. A combination of one or more $IK_r$ channel blockers and of one or more compounds of the formula Ia or Ib



Ia



Ib

or physiologically tolerable salts thereof,

in which

R(1) is alkyl having 3, 4 or 5 carbon atoms or quinolinyl,

R(2) is alkyl having 1, 2, 3 or 4 carbon atoms or cyclopropyl;

R(3) is phenyl or pyridyl,

where phenyl and pyridyl are unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, $CF_3$, $OCF_3$, alkyl having 1, 2 or 3 carbon atoms and alkoxy having 1, 2 or 3 carbon atoms;

A is $-C_nH_{2n}-$;

n is 0, 1 or 2;

R(4), R(5), R(6) and R(7)

independently of one another are hydrogen, F, Cl, $CF_3$, $OCF_3$, CN, alkyl having 1, 2 or 3 carbon atoms, or alkoxy having 1, 2 or 3 carbon atoms;

B is $-C_mH_{2m}-$;

m is 1 or 2;

R(8) is alkyl having 2 or 3 carbon atoms, phenyl or pyridyl,

where phenyl and pyridyl are unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, $CF_3$, $OCF_3$, alkyl having 1, 2 or 3 carbon atoms and alkoxy having 1, 2 or 3 carbon atoms;

R(9) is C(O)OR(10) or COR(10);

R(10) is $-C_xH_{2x}$-R(11);

x is 0, 1 or 2; and

R(11) is phenyl,

where phenyl is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, $CF_3$, $OCF_3$, alkyl having 1, 2 or 3 carbon atoms and alkoxy having 1, 2 or 3 carbon atoms

2. The combination as claimed in claim 1, wherein the $IK_r$ blockers are selected from the group consisting of
dofetilide, ibutilide, almokalant, dl-sotalol, d-sotalol, azimilide, amiodarone, E4031, clofilium, ambasilide, MS551, tedisamil, bertosamil and quinidine.

3. The combination as claimed in claim 2, the $IK_r$ blockers being selected from the group consisting of
dofetilide, ibutilide, almokalant, dl-sotalol, d-sotalol, amiodarone and quinidine.

4. The combination as claimed in claim 1, the $IK_r$ blockers being selected from the group consisting of
dofetilide, ibutilide, almokalant, dl-sotalol, d-sotalol, amiodarone and quinidine and the compounds of the formula Ia or Ib being selected from the group consisting of
2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide,
2'-(benzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 2-(2-pyridyl)-ethylamide,
2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid 2,4-difluoro-benzylamide,

(S)-2'-(α-methylbenzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 2-(2-pyridyl)ethylamide,
2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide,
2-(butyl-1-sulfonylamino)-N-(cyclopropylpyridin-3-ylmethyl)-5-methylbenz-amide,
(S)-5-fluoro-2-(quinoline-8-sulfonylamino)-N-(1-phenylpropyl)benzamide and their physiologically tolerable salts.

5. The combination as claimed in claim 1, comprising:
2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide and ibutilide,
2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide and dofetilide,
2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide and amiodarone,
2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide and ibutilide,
2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide and dofetilide,
2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide and amiodarone,
2-(butyl-1-sulfonylamino)-N-(cyclopropylpyridin-3-ylmethyl)-5-methylbenz-amide and ibutilide,
2-(butyl-1-sulfonylamino)-N-(cyclopropylpyridin-3-ylmethyl)-5-methylbenz-amide and dofetilide,
2-(butyl-1-sulfonylamino)-N-(cyclopropylpyridin-3-ylmethyl)-5-methylbenz-amide and amiodarone,
(S)-5-fluoro-2-(quinoline-8-sulfonylamino)-N-(1-phenylpropyl)benzamide and ibutilide,
(S)-5-fluoro-2-(quinoline-8-sulfonylamino)-N-(1-phenylpropyl)benzamide and dofetilide,

(S)-5-fluoro-2-(quinoline-8-sulfonylamino)-N-(1-phenylpropyl)benzamide and amiodarone,
or the physiologically tolerable salts thereof.

6. A pharmaceutical preparation comprising a combination as claimed in claim 1 as active compound, together with pharmaceutically acceptable vehicles or additives and, optionally, one or more other pharmacologically active compounds.

7. A pharmaceutical product comprising one or more $IK_r$ channel blockers together with one or more compounds of the formula Ia or Ib, or physiologically tolerable salts thereof, as set forth in claim 1 for simultaneous, separate or sequential administration for the therapy or prophylaxis of atrial fibrillation or atrial flutters.

8. A method for the therapy or prophylaxis of atrial fibrillation or atrial flutters comprising the simultaneous, separate or sequential administration of a combination as claimed in claim 1.

9. The method as claimed in claim 8, wherein in said combination the $IK_r$ blockers are selected from the group consisting of
dofetilide, ibutilide, almokalant, dl-sotalol, d-sotalol, azimilide, amiodarone, E4031, clofilium, ambasilide, MS551, tedisamil, bertosamil and quinidine.

10. The method as claimed in claim 9, wherein in said combination the $IK_r$ blockers are selected from the group consisting of
dofetilide, ibutilide, almokalant, dl-sotalol, d-sotalol, amiodarone and quinidine.

11. The method as claimed in claim 8, wherein in said combination the $IK_r$ blockers are selected from the group consisting of dofetilide, ibutilide, almokalant, dl-sotalol, d-sotalol, amiodarone and quinidine and the compounds of the formula Ia or Ib are selected from the group consisting of

2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide,
2'-(benzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 2-(2-pyridyl)-ethylamide,
2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid 2,4-difluoro-benzylamide,
(S)-2'-(α-methylbenzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 2-(2-pyridyl)ethylamide,
2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide,
2-(butyl-1-sulfonylamino)-N-(cyclopropylpyridin-3-ylmethyl)-5-methylbenz-amide,
(S)-5-fluoro-2-(quinoline-8-sulfonylamino)-N-(1-phenylpropyl)benzamide
and their physiologically tolerable salts.

12. The method as claimed in claim 8, the combination comprising:
2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide and ibutilide,
2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide and dofetilide,
2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide and amiodarone,
2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide and ibutilide,
2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide and dofetilide,
2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide and amiodarone,
2-(butyl-1-sulfonylamino)-N-(cyclopropylpyridin-3-ylmethyl)-5-methylbenz-amide and ibutilide,
2-(butyl-1-sulfonylamino)-N-(cyclopropylpyridin-3-ylmethyl)-5-methylbenz-amide and dofetilide,

2-(butyl-1-sulfonylamino)-N-(cyclopropylpyridin-3-ylmethyl)-5-methylbenz-amide and amiodarone,

(S)-5-fluoro-2-(quinoline-8-sulfonylamino)-N-(1-phenylpropyl)benzamide and ibutilide,

(S)-5-fluoro-2-(quinoline-8-sulfonylamino)-N-(1-phenylpropyl)benzamide and dofetilide,

(S)-5-fluoro-2-(quinoline-8-sulfonylamino)-N-(1-phenylpropyl)benzamide and amiodarone,

or the physiologically tolerable salts thereof.